Darrell Tan

MD, FRCPC, PhD

Scientist

Biography

Dr. Darrell Tan is an infectious diseases physician, clinician-scientist and Canadian Institutes of Health Research (CIHR) New Investigator whose research focuses on clinical trials in human immunodeficiency virus (HIV) prevention and HIV/sexual transmitted infection (STI) co-infection. As Director of the University of Toronto Clinical Research Unit on HIV Prevention and co-leader of the CIHR Canadian HIV Trials Network Biomedical Prevention Working Group, he is leading multiple efforts to optimize the implementation of HIV pre- and post-exposure prophylaxis (PrEP and PEP) in Canada. These include Canada’s first demonstration project of daily oral TDF/FTC-based PrEP in Toronto MSM, the development of national Clinical Practice Guidelines on PEP & PrEP use, exploration of the relationship between syndemic health problems and clinical outcomes of PEP & PrEP, studies of nurse-led PEP & PrEP, and evaluations of novel antiretroviral PEP regimens.

Additional research interests are in the interaction between HIV and common co-infections such as herpes simplex virus type 2 (HSV-2) and syphilis, and the role of systemic inflammation in driving clinical outcomes in people living with HIV. He is also Co-Principle Investigator on two CIHR-supported multicentre randomized control trials including the a trial of anti-herpes medication for attenuating HIV disease progression, and a trial of enhanced syphilis screening in HIV-positive men.

Recent Publications

  1. Hart, TA, Noor, SW, Berlin, GW, Skakoon-Sparling, S, Tavangar, F, Tan, D et al.. Pre-exposure prophylaxis and bacterial sexually transmitted infections (STIs) among gay and bisexual men. Sex Transm Infect. 2022; :. doi: 10.1136/sextrans-2021-055381. PubMed PMID:35701145 .
  2. Gaspar, M, Wells, A, Hull, M, Tan, DHS, Lachowsky, N, Grace, D et al.. "What other choices might I have made?": Sexual Minority Men, the PrEP Cascade and the Shifting Subjective Dimensions of HIV Risk. Qual Health Res. 2022; :10497323221092701. doi: 10.1177/10497323221092701. PubMed PMID:35616240 .
  3. Chambers, C, Deeks, SL, Sutradhar, R, Cox, J, de Pokomandy, A, Grennan, T et al.. Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada. Vaccine. 2022;40 (26):3690-3700. doi: 10.1016/j.vaccine.2022.05.019. PubMed PMID:35577633 .
  4. Xi, M, Bullock, S, Mendelsohn, JB, Iveniuk, J, Moravan, V, Burchell, AN et al.. A national recruitment strategy for HIV-serodiscordant partners living in Canada for the Positive Plus One study: a mixed-methods study. BMC Public Health. 2022;22 (1):832. doi: 10.1186/s12889-022-13153-5. PubMed PMID:35473617 PubMed Central PMC9040331.
  5. Mendelsohn, JB, Calzavara, L, Bullock, S, Iveniuk, J, Tan, DHS, Burchell, AN et al.. Disclosure of HIV-serodiscordant relationships and association with viral suppression: results from the Positive Plus One study. AIDS Care. 2022; :1-8. doi: 10.1080/09540121.2021.2019669. PubMed PMID:35416092 .
  6. Truong, R, Tang, V, Grennan, T, Tan, DHS. A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora. JAC Antimicrob Resist. 2022;4 (1):dlac009. doi: 10.1093/jacamr/dlac009. PubMed PMID:35198979 PubMed Central PMC8855662.
  7. Christensen, BL, Tan, DH. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV. Expert Opin Pharmacother. 2022;23 (4):439-446. doi: 10.1080/14656566.2022.2029409. PubMed PMID:35073817 .
  8. Ali, K, Azher, T, Baqi, M, Binnie, A, Borgia, S, Carrier, FM et al.. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194 (7):E242-E251. doi: 10.1503/cmaj.211698. PubMed PMID:35045989 PubMed Central PMC8863204.
  9. Costiniuk, CT, Singer, J, Langlois, MA, Kulic, I, Needham, J, Burchell, A et al.. CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. BMJ Open. 2021;11 (12):e054208. doi: 10.1136/bmjopen-2021-054208. PubMed PMID:34916326 PubMed Central PMC8678543.
  10. Tan, DHS, Rana, J, Tengra, Z, Hart, TA, Wilton, J, Bayoumi, AM et al.. Preferences regarding emerging HIV prevention technologies among Toronto men who have sex with men: a discrete choice experiment. Sci Rep. 2021;11 (1):22252. doi: 10.1038/s41598-021-01634-3. PubMed PMID:34782691 PubMed Central PMC8592986.
Search PubMed

Affiliations & Other Activities

  • Clinician-Scientist, Department of Medicine, St. Michael’s Hospital
  • Assistant Professor, Department of Medicine, University of Toronto
  • Assistant Professor, Institute of Health Policy, Management & Evaluation, University of Toronto
  • Director, HIV Prevention Clinical Research Unit, University of Toronto
  • Affiliate Scientist, Toronto General Research Institute